Benzinga | May 24, 2021 07:07AM EDT

Myriad Genetics to Sell its Myriad RBM to Q2 Solutions, Terms Not Disclosed

"Our agreement with Q2 Solutions provides a good home for Myriad RBM teammates, delivers strong value, and provides significant capital for future growth," said Paul J. Diaz, president and CEO of Myriad Genetics. "The divestiture of Myriad RBM, along with other announced divestitures, allows us to accelerate the execution of our transformation plan and focus on advancing our core businesses in Women's Health, Oncology and Mental Health."